Analyst firms · Evercore ISI · RARE

Evercore ISI RARE price target and rating history

Ultragenyx Pharmaceutical Inc. (RARE) · Health Care

Evercore ISI rates Ultragenyx Pharmaceutical Inc. (RARE) In-line with a $16 price target, as of its latest action on Sep 3, 2026. It has published 3 rating actions on RARE since August 2022, including 1 upgrade and 2 downgrades. Across 5 firms with a RARE price target in the last 12 months, the median target is $16. Evercore ISI's target matches it.

Current rating

In-line

Price target

$16

Median target, all firms

$16

Actions on RARE

3

Evercore ISI price target on RARE

Every Evercore ISI rating on RARE

• Sep 3, 2026
  DowngradeEvercore ISI downgrades to In-line from Outperform, price target $16
• Jun 6, 2023
  UpgradeEvercore ISI upgrades to Outperform from In-line, price target $60 to $80
• Aug 1, 2022
  DowngradeEvercore ISI downgrades to In-line from Outperform, price target $95 to $60

How other firms rate RARE

Each firm's latest rating and stated target in the last 12 months.

Questions about Evercore ISI and RARE

What is Evercore ISI's price target for RARE?

Evercore ISI's latest stated price target for Ultragenyx Pharmaceutical Inc. (RARE) is $16, from its action on Sep 3, 2026.

What is Evercore ISI's rating on RARE?

Evercore ISI rates RARE In-line, a neutral rating, as of Sep 3, 2026.

When did Evercore ISI last change its view on RARE?

On Sep 3, 2026, Evercore ISI downgrades to In-line from Outperform, price target $16.

How does Evercore ISI's RARE target compare with other analysts?

Across 5 firms with a RARE price target in the last 12 months, the median target is $16. Evercore ISI's target matches it.

More RARE rating histories

• Wells Fargo3
• H.C. Wainwright3

All Evercore ISI ratingsRARE news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.